BC Innovations | Sep 12, 2019
Distillery Therapeutics

Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer Delivering chemotherapies through conjugation to tumor-targeted albumin could treat breast and colorectal cancers. Albumin is fused with collagen-binding domain of vWF to facilitate attachment to the tumor...
BioCentury | Oct 6, 2017

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Week In Review | Jun 16, 2017
Clinical News

CytRx's aldoxorubicin misses OS endpoint in Phase III to treat STS

CytRx Corp. (NASDAQ:CYTR) reported additional data from a Phase III trial in 433 patients with metastatic, locally advanced or unresectable soft tissue sarcoma (STS) showing that 350 mg/m 2 IV aldoxorubicin on day 1 of...
BC Week In Review | Apr 26, 2017
Clinical News

Aldoxorubicin regulatory update

CytRx said FDA agreed with the company’s planned NDA pathway for aldoxorubicin to treat soft tissue sarcoma (STS) and did not request any additional trials for the candidate. The company hopes to submit a rolling...
BC Week In Review | Jan 6, 2017
Clinical News

Aldoxorubicin: Additional Ph III data

Additional data from an open-label, international Phase III trial in 433 patients with metastatic, locally advanced or unresectable STS showed that 350 mg/m 2 IV aldoxorubicin on day 1 of each 21-day cycle met the...
BC Week In Review | Oct 24, 2016
Clinical News

Aldoxorubicin: Interim Phase Ib/II data

Interim data from 36 evaluable patients with advanced sarcomas in an open-label, U.S. Phase Ib/II trial showed that 170 and 250 mg/m2 doses of aldoxorubicin plus ifosfamide and mesna led to an ORR of 36%,...
BioCentury | Oct 3, 2016

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BioCentury | Oct 3, 2016

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Sep 12, 2016
Clinical News

Aldoxorubicin: Completed Phase IIb enrollment

CytRx completed enrollment of 132 patients with SCLC who have relapsed or were refractory to prior chemotherapy in an open-label, international Phase IIb trial comparing 230 mg/m 2 IV aldoxorubicin given on day 1 of...
Items per page:
1 - 10 of 75